Vivo Capital Fund VIII, L.P.

CIK 1618788 · last filed 2022-08-16

Vivo Capital Fund VIII, L.P. is a corporate insider who has filed 8 SEC Form 4 insider transactions across 5 companies since 2017. The most recent filing, for TERN, was dated Apr 3, 2024. Across all open-market trades the lifetime net is +$104.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $206.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$206.14M

Companies

5

Total Filings

8

Lifetime Open-Market Net

$104.47M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Terns Pharmaceuticals, Inc. (TERN) Delisted	10%+ Owner	281,223	$52.95	$14.89M	$75.28M	2	2022-08-16
IPI Legacy Liquidation Co (IMPL) Delisted	10%+ Owner	1,625,022	$0.24	$391.8K	$25.88M	1	2021-04-29
CRNX	10%+ Owner	2,458,445	$83.85	$206.14M	-$12.68M	1	2020-04-07
VYNE Therapeutics Inc. (MNLO) Delisted	10%+ Owner	3,524,541	—	—	$15.00M	1	2018-01-29
Timber Pharmaceuticals, Inc. (BPMX) Delisted	10%+ Owner	1,174,695	—	—	$1.00M	1	2017-05-01

Recent Filings

8 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2024-04-03	Terns Pharmaceuticals, Inc. (TERN) Delisted	Notice (144)	−39,416	-$236.5K	EDGAR
2024-04-01	Terns Pharmaceuticals, Inc. (TERN) Delisted	Notice (144)	−63,956	-$454.7K	EDGAR
2022-08-16	Terns Pharmaceuticals, Inc. (TERN) Delisted	Buy (P)	+13,121,195	$34.90M	EDGAR
2021-04-29	IPI Legacy Liquidation Co (IMPL) Delisted	Mixed	+8,654,367	$29.98M	EDGAR
2021-02-09	Terns Pharmaceuticals, Inc. (TERN) Delisted	Mixed	+13,375,665	$40.38M	EDGAR
2020-04-07	CRNX	Sell (S)	−918,345	-$12.68M	EDGAR
2018-01-29	VYNE Therapeutics Inc. (MNLO) Delisted	Mixed	+12,033,708	$15.00M	EDGAR
2017-05-01	Timber Pharmaceuticals, Inc. (BPMX) Delisted	Buy (P)	+1,282,052	$1.00M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.